Production (Stage)
Zentalis Pharmaceuticals, Inc.
ZNTL
$1.20
-$0.04-3.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.28M | -94.97M | -40.16M | -88.28M | 10.07M |
| Total Depreciation and Amortization | 262.00K | 317.00K | 321.00K | 327.00K | 324.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.63M | 29.09M | 3.05M | 38.71M | -46.83M |
| Change in Net Operating Assets | 1.75M | -7.08M | -7.26M | 14.10M | -15.53M |
| Cash from Operations | -32.64M | -39.70M | -44.05M | -35.14M | -51.97M |
| Capital Expenditure | -- | 0.00 | 0.00 | -181.00K | -40.00K |
| Sale of Property, Plant, and Equipment | 5.00K | 0.00 | 0.00 | 65.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 40.47M | 32.28M | 48.24M | 34.61M | 61.59M |
| Cash from Investing | 40.48M | 32.28M | 48.24M | 34.49M | 61.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 189.00K | 0.00 | 92.00K | 9.00K | 248.00K |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | 0.00 | -241.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 189.00K | 0.00 | 92.00K | 9.00K | 7.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.03M | -7.42M | 4.29M | -640.00K | 9.58M |